The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Background and objectives: Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD. Design, setting, participants, & measurements: Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D. Results: Median GFR was 66.5 (interquartile range, 40.0–88.3) ml/min per 1.73 m 2. Median sclerostin level was 53.5 (interquartile range, 37.5–77.2) pmol/L, was higher in patients with a GFR <60 ml/min per 1.73 m 2, and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (P<0.05). An inverse relationship was found between sclerostin and GFR (r=−0.58; P<0.001), and a positive correlation was seen with age (r=0.34; P<0.01) and serum phosphate (r=0.26; P=0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (P<0.001). Age lost its relationship with sclerostin level. Conclusions: This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Osteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
Cited by
Shi, T., Shen, S., Shi, Y., Wang, Q., Zhang, G., Lin, J., Chen, J., Bai, F., Zhang, L., Wang, Y., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00989-x · Cited by 87
“In addition to ageing, high serum sclerostin levels also exist in various disorders, such as type 2 diabetes, liver disease, kidney disorders, osteoarthritis, etc. 21,22,47,48 .”
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
The Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
“Compared to healthy individuals, end-stage renal disease (ESRD) patients have serum sclerostin levels that are three to four times higher [103,104].”
Background
Metadata
- Authors
- Pelletier, S., Dubourg, L., Carlier, M.-C., Hadj-Aissa, A., & Fouque, D.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2013-05
- Volume
- 8
- Issue
- 5
- Pages
- 819-823
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2154847297
- Cited by
- 196
- References
- 2
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.